Acticor Biotech's Series A Round

Acticor Biotech raised a round of funding on January 04, 2018.

Acticor Biotech is developing an anti-thrombotic agent without bleeding risk for the emergency treatment of ischemic strokes. Its ACT-017 inhibits a new target protein, the glycoprotein VI, which is s…

Articles about Acticor Biotech's Series A Round: